BioPharma Watchlist: VRX, JAZZ, ARNA, CELG, ELN, MRK

Aug. 08, 2010 11:59 PM ETBHC, JAZZ, PFE, CELG, ELN, MRK
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2009

I hold degrees in Biochemistry and Business from NC State University in the heart of RTP, NC. My work experience has been in Microbiology and Pharmacy. I have experience with FDA decisions and Clinical Trials. Presently a mergers and acquisitions data analyst for a healthcare firm.   See Seeking Alpha's policy on anonymous authors:

Stocks currently on my Watchlist for top BioPharma plays in the near future.

1. Valeant Pharmaceuticals (NYSE:VRX)

Biotechnology Research Report on Valeant's Potiga

On August 11, 2010, we expect the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee to review the marketing application of Valeant Pharmaceuticals International’s (VRX) Potiga (formerly known as Retigabine), designed for the treatment of partial-onset seizures in epilepsy patients who have become refractory (failing to show response to prior therapy) to anti-epilepsy drugs (AEDs).

2. Jazz Pharma (Nasdaq:JAZZ) upcoming FDA review for JZP-6 August 20th for the treatment of Fibramyalgia

3. Arena Pharma (NASDAQ:ARNA) upcoming FDA review for weight loss drug Lorcaserin Sept 16th

4. Celgene (Nasdaq: CELG)

Celgene's Product Pipeline, which aquired Abraxis on June 30th, and recently gained anti-trust approval to buy Abraxis for 2.9B to improve their cancer pipeline.

Abraxis is currently one of the few companies with FDA approved nanotechnolgy based cancer treatment with Abraxis' Breast Cancer Drug Abraxane

5. Elan Drug Technologies (NYSE:ELN)

NanaoCrystal Technology with five products launched, US $1.8B+ annual in-market sales. Elan Corporation has taken a huge hit in the past going from a peak of 8.18 in April 2010 to 5.25 today. I see a potential upswing happening.

6. Merck (NYSE: MRK)

With former Schering-Plough's drug pipeline Merck is a consistent winner in the Pharmaceutical market. Merck's Research Pipeline from May 2010

Schering-Plough has exclusive rights to the ovarian cancer medication, an approved nanodrug Pegylated Liposomal Doxorubicinwhich is marketed as Doxil in the U.S. by Centocor Ortho Biotech and in Israel by Janssen-Cilag that has progressed or recurred after platinum-based chemotherapy. Merck has a large women's specific drug market for Infertility, Ovarian Cancer, and Cervical Cancer

On a side note, here is an interesting article about Small Biotech Plays earlier this year that are still relevent today.

Top 10 Small Cap. Biotech Performers: April 7, 2010 – May 7, 2010



To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.